Keywords
CRISPR-Cas9
Pancreatic beta cells
Insulin
Gene editing technology
Human pluripotent stem cells
Submitted : 2024-06-09
Accepted : 2024-06-24
Published : 2024-07-09
Abstract
Diabetes mellitus (DM) is a metabolic condition that raises blood glucose levels (hyperglycemia) without insulin or insulin receptor defects. Insulin is a peptide hormone the pancreatic beta cells produce and controls blood glucose levels. The defective immune system engulfs the beta cells of the pancreas, causing no insulin production or the insulin receptors to become faulty, resulting in insulin resistance. There are two main types of diabetes mellitus: type 1 diabetes mellitus and type 2 diabetes mellitus. In type 1 diabetes mellitus, the beta cells are engulfed by the defective immune system; hence the insulin production stops, and in type 2 diabetes mellitus, there is a defect in the insulin receptor that causes insulin resistance. Both types of diabetes cause uncontrolled blood sugar levels, which can lead to severe damage to vital body organs such as the heart, kidney, limbs, eyes, and nerves. The diseases of these organs are cardiovascular diseases, nephropathy, retinopathy, neuropathy, high blood pressure, and obesity. There are several methods to treat diabetes mellitus, such as islet cell transplant, tablets and medication, insulin pumps, weight loss surgery, insulin, diet and exercise, and emotional support. However, the medicines involved in traditionally treating diabetes mellitus are finerenone, tirzepatide, and, GLP-1 receptor, SGLT-2 inhibitors. These medicines cause severe damage to the body, such as cardiovascular death, transient ischemic attack, end-stage kidney diseases, and limb removal (amputation). Therefore, a new modern gene editing technology such as clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) is involved in treating diabetes. In this technology, gene editing occurs in the human pluripotent stem cells (hiPSCs) taken from the patient’s body; these cells are converted into improved pancreatic beta cells. There are different methods involved, including cell-based therapies (such as stem cells and brown adipocytes), targeting specific genes associated with diabetes. This paper presents a critical review of the gene-editing tool CRISPR/Cas9 technology for the treatment of diabetes mellitus.
References
Wadghiri MZ, Idri A, El Idrissi T, et al., 2022, Ensemble Blood Glucose Prediction in Diabetes Mellitus: A Review. Computers in Biology and Medicine, (147): 105674.
Gregg E, Buckley J, Ali MK, et al., 2023, Improving Health Outcomes of People with Diabetes Mellitus: Global Target Setting to Reduce the Burden of Diabetes Mellitus by 2030. Lancet (London, England), 401(10384): 1302.
Liu R, Li L, Shao C, et al., 2022, The Impact of Diabetes on Vascular Disease: Progress from the Perspective of Epidemics and Treatments. Journal of Diabetes Research, (2022): 1531289.
Sahin B, llgin G, 2022, Risk Factors of Deaths Related to Cardiovascular Diseases in World Health Organization (WHO) Member Countries. Health & Social Care in the Community, 30(1): 73–80.
Hajam YA, Rani R, Malik JA, et al., 2022, Diabetes Mellitus: Signs and Symptoms, Epidemiology, Current Prevention, Management Therapies, and Treatments, in Antidiabetic Potential of Plants in the Era of Omics, Apple Academic Press, New Jersey, 31–77.
Syarifuddin S, Samosir W, 2022, Characteristics of Types of Diabetes Mellitus II in Regional General Hospital Than Rondahaim, Simalungun District. Medalion Journal: Medical Research, Nursing, Health and Midwife Participation, 3(4): 144–148.
Yokoyama H, Araki SI, Yamazaki K, et al., 2022, Trends in Glycemic Control in Patients with Insulin Therapy Compared with Non-Insulin or No Drugs in Type 2 Diabetes in Japan: A Long-Term View of Real-World Treatment Between 2002 and 2018 (JDDM 66). BMJ Open Diabetes Research and Care, 10(3): e002727.
Chavda VP, Ajabiya J, Teli D, et al., 2022, Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules, 27(13): 4315.
Shi Q, Nong K, Vandvik PO, et al., 2023, Benefits and Harms of Drug Treatment for Type 2 Diabetes: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. BMJ, (381): e074068.
Bora J, Dey A, Lyngdoh AR, et al., 2023, A Critical Review on Therapeutic Approaches of CRISPR-Cas9 in Diabetes Mellitus. Naunyn-Schmiedeberg’s Archives of Pharmacology, 396(12): 3459–3481.
Ahlqvist E, Prasad RB, Groop L, 2022, 100 Years of Insulin: Towards Improved Precision and a New Classification of Diabetes Mellitus. Journal of Endocrinology, 252(3): R59–R70.
Smith F, Sabri AH, Heppel M, et al., 2022, The Clinical and Translational Prospects of Microneedle Devices, with a Focus on Insulin Therapy for Diabetes Mellitus as a Case Study. International Journal of Pharmaceutics, (628): 122234.
Tomic D, Shaw JE, Magliano DJ, 2022, The Burden and Risks of Emerging Complications of Diabetes Mellitus. Nature Reviews Endocrinology, 18(9): 525–539.
Huang Q, Yang D, Deng H, et al., 2022, Association Between Metabolic Syndrome and Microvascular Complications in Chinese Adults with Type 1 Diabetes Mellitus. Diabetes & Metabolism Journal, 46(1): 93.
Khadilkar A, Oza C, Mondkar SA, 2023, Insulin Resistance in Adolescents and Youth with Type 1 Diabetes: A Review of Problems and Solutions. Clinical Medicine Insights: Endocrinology and Diabetes, (16): 11795514231206730.
Karamanakos G, Kokkinos A, Dalamaga M, et al., 2022, Highlighting the Role of Obesity and Insulin Resistance in Type 1 Diabetes and Its Associated Cardiometabolic Complications. Current Obesity Reports, 11(3): 180–202.
Ahmad E, Lim S, Lamptey R, et al., 2022, Type 2 Diabetes. The Lancet, 400(10365): 1803–1820.
Moon JH, Jang HC, 2022, Gestational Diabetes Mellitus: Diagnostic Approaches and Maternal-Offspring Complications. Diabetes & Metabolism Journal, 46(1): 3.
Echouffo-Tcheugui JB, Perreault L, Ji L, et al., 2023, Diagnosis and Management of Prediabetes: A Review. Jama, 329(14): 1206–1216.
Cheng Y, Wang H, Li M, 2023, The Promise of CRISPR/Cas9 Technology in Diabetes Mellitus Therapy: How Gene Editing is Revolutionizing Diabetes Research and Treatment. Journal of Diabetes and its Complications, 37(8): 108524.
Azeem S, Khan U, Liaquat A, 2022, The Increasing Rate of Diabetes in Pakistan: A Silent Killer. Annals of Medicine and Surgery, (79): 103901.
Bhutta ZA, Haq ZU, Basit A, 2022, Diabetes in Pakistan: Addressing the Crisis. The Lancet Diabetes & Endocrinology, 10(5): 309–310.
Adnan M, Aasim M, 2020, Prevalence of Type 2 Diabetes Mellitus in the Adult Population of Pakistan: A Meta-Analysis of Prospective Cross-Sectional Surveys. Annals of Global Health, 86(1): 7.
Pfannkuche A, Alhajjar A, Ming A, et al., 2020, Prevalence and Risk Factors of Diabetic Peripheral Neuropathy in a Diabetics Cohort: Register Initiative “Diabetes and Nerves.” Endocrine and Metabolic Science, 1(1–2): 100053.
Wang Y, Lin Z, Zhai G, et al., 2022, Prevalence of and Risk Factors for Diabetic Retinopathy and Diabetic Macular Edema in Patients with Early-and Late-Onset Diabetes Mellitus. Ophthalmic Research, 65(3): 293–299.
Braffett BH, Gubitosi-Klug RA, Albers JW, et al., 2020, Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes, 69(5): 1000–1010.
Méndez-Morales S, Pérez-De Marcos J, Rodríguez-Cortés O, et al., 2022, Diabetic Neuropathy: Molecular Approach a Treatment Opportunity. Vascular Pharmacology, (143): 106954.
Sawaf H, Thomas G, Taliercio JJ, et al., 2022, Therapeutic Advances in Diabetic Nephropathy. Journal of Clinical Medicine, 11(2): 378.
Liu XJ, Hu XK, Yang H, et al., 2022, A Review of Traditional Chinese Medicine on Treatment of Diabetic Nephropathy and the Involved Mechanisms. The American Journal of Chinese Medicine, 50(07): 1739–1779.
Tan TE, Wong TY, 2023, Diabetic Retinopathy: Looking Forward to 2030. Frontiers in Endocrinology, (13): 1077669.
Fung TH, Patel B, Wilmot EG, et al., 2022, Diabetic Retinopathy for the Non-Ophthalmologist. Clinical Medicine, 22(2): 112.
Marks BE, Williams KM, Sherwood JS, et al., 2022, Practical Aspects of Diabetes Technology Use: Continuous Glucose Monitors, Insulin Pumps, and Automated Insulin Delivery Systems. Journal of Clinical & Translational Endocrinology, (27): 100282.
Deng Y, Hou Y, Wu L, et al., 2022, Effects of Diet and Exercise Interventions to Prevent Gestational Diabetes Mellitus in Pregnant Women with High-Risk Factors in China: A Randomized Controlled Study. Clinical Nursing Research, 31(5): 836–847.
Chinese Clinical Guidelines for the Prevention and Treatment of Type 2 Diabetes in the Elderly Editorial Group, Chinese Society of Geriatrics Geriatric Endocrinology and Metabolism Branch, Chinese Society of Geriatric Health Care Medicine Geriatric Endocrinology and Metabolism Branch, etc., 2022, Clinical Guidelines for Prevention and Treatment of Type 2 Diabetes Mellitus in the Elderly in China (2022 Edition). Chinese Journal of Internal Medicine, 61(1): 12–50.
Chiou TT, Ge Y, Romley JA, 2023, Trends in Metformin Use Among Patients with Prediabetes: 2008–2020. Diabetes care, 46(1): e1–e2.
Syafhan NF, Donnelly R, Harper R, et al., 2022, Adherence to Metformin in Adults with Type 2 Diabetes: A Combined Method Approach. Journal of Pharmaceutical Policy and Practice, 15(1): 61.
Zhuang W, Lv J, Liang Q, et al., 2020, Adverse Effects of Gestational Diabetes-Related Risk Factors on Pregnancy Outcomes and Intervention Measures. Experimental and Therapeutic Medicine, 20(4): 3361–3367.
Wang JY, Doudna JA, 2023, CRISPR Technology: A Decade of Genome Editing is Only the Beginning. Science, 379(6629): eadd8643.
van Beljouw SP, Sanders J, Rodríguez-Molina A, et al., 2023, RNA-Targeting CRISPR–Cas Systems. Nature Reviews Microbiology, 21(1): 21–34.
Pan S, Zhang H, 2021, Discovery in CRISPR-Cas9 System. Journal of Central South University Medical Edition, 46(12): 1392–1402.
Garcia-Robledo JE, Barrera MC, Tobón GJ, 2020, CRISPR/Cas: From Adaptive Immune System in Prokaryotes to Therapeutic Weapon Against Immune-Related Diseases: CRISPR/Cas9 Offers a Simple and Inexpensive Method for Disease Modeling, Genetic Screening, and Potentially for Disease Therapy. International Reviews of Immunology, 39(1): 11–20.
Nestor MW, Wilson RL, 2022, Brief Introduction to CRISPR Cas9, in Anticipatory Ethics and the Use of CRISPR in Humans, Springer, Berlin, 1–24.
Li T, Yang Y, Qi H, et al., 2023, CRISPR/Cas9 Therapeutics: Progress and Prospects. Signal Transduction and Targeted Therapy, 8(1): 36.
Liao C, Beisel CL, 2021, The TracrRNA in CRISPR Biology and Technologies. Annual Review of Genetics, (55): 161–181.
Nussenzweig PM, Marraffini LA, 2020, Molecular Mechanisms of CRISPR-Cas Immunity in Bacteria. Annual Review of Genetics, (54): 93–120.
Jacinto FV, Link W, Ferreira BI, 2020, CRISPR/Cas9-Mediated Genome Editing: From Basic Research to Translational Medicine. Journal of Cellular and Molecular Medicine, 24(7): 3766–3778.
Chatterjee P, Lee J, Nip L, et al., 2020, A Cas9 with PAM Recognition for Adenine Dinucleotides. Nature Communications, 11(1): 2474.
Gaj T, 2021, Next-generation CRISPR Technologies and Their Applications in Gene and Cell Therapy. Trends in Biotechnology, 39(7): 692–705.
Kim J, Lee S, Baek K, et al., 2020, Site-Specific Gene Knock-Out and On-Site Heterologous Gene Overexpression in Chlamydomonas reinhardtii Via a CRISPR-Cas9-Mediated Knock-In Method. Frontiers in Plant Science, (11): 306.
Bora J, Malik S, Kishore S, et al., 2023, Therapeutic Applications of CRISPR-Cas9 in Diabetes Mellitus: A Perspective Review. Minerva Biotechnology & Biomolecular Research, 35(4): 238–249.
El Nahas R, Al-Aghbar MA, Herrero L, et al., 2023, Applications of Genome-Editing Technologies for Type 1 Diabetes. International Journal of Molecular Sciences, 25(1): 344.
Bevacqua RJ, Dai X, Lam JY, et al., 2021, CRISPR-Based Genome Editing in Primary Human Pancreatic Islet Cells. Nature Communications, 12(1): 2397.
Liu G, David BT, Trawczynski M, et al., 2020, Advances in Pluripotent Stem Cells: History, Mechanisms, Technologies, and Applications. Stem Cell Reviews and Reports, 16(1): 3–32.
Pop-Bica C, Nutu A, Cojocneanu R, et al., 2022, The CRISPR/Cas9 Genome-Editing System: Principles and Applications. In CRISPR-/Cas9 Based Genome Editing for Treating Genetic Disorders and Diseases, CRC Press, Florida, 1–22.
Ueki K, Nishida Y, Aoyama S, et al., Establishment of Pancreatic Beta Cell-Specific Gene Knockout System Based on CRISPR. Diabetes, 72(11): 1609–1620.
Taha EA, Lee J, Hotta A, 2022, Delivery of CRISPR-Cas Tools for In Vivo Genome Editing Therapy: Trends and Challenges. Journal of Controlled Release, (342): 345–361.